DJI136

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Extensive stage small cell lung cancerExtensive-stage Small Cell Lung Cancer (ES-SCLC)

Phase 1

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

RecruitingNCT07564401

Novartis PharmaceuticalsExtensive-stage Small Cell Lung Cancer (ES-SCLC)

Start: 2026-06-16End: 2031-03-03Target: 80Updated: 2026-09-11

A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

Not yet recruitingCTIS2025-523276-23-00

Novartis Pharma AGExtensive stage small cell lung cancer

Target: 11Updated: 2026-05-27